AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33191157
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation by a pharmacy team
Trial: 33216238
Drug: Sufentanil sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil sublingual tablet system (SSTS)
Trial: 35611515
Drug: Additional antiemetic
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional antiemetic drug use
Trial: 33110039
Drug: E2/P4 1/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/P4 1/100 mg/mg
Trial: 33110039
Drug: E2/P4 0.5/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/P4 0.5/100 mg/mg
Trial: 33215755
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants with a provisional fixed prosthesis
Trial: 34144359
Drug: No surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surface treatment (CTRL)
Trial: 35150243
Drug: Dopamine D2/D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2/D3 receptor availability
Trial: 36017827
Drug: Multi-day rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multi-day rivastigmine transdermal patch (RID-TDS), applied on a 4-3-4 day regimen for 11 consecutive days.
Trial: 36017827
Drug: Exelon® transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exelon® transdermal patch, applied daily for 11 consecutive days.
Trial: 34758251
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase followed by EVT
Trial: 32320401
Drug: Febuxostat (10-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (10-60 mg daily)
Trial: 34821978
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral hygiene motivation only)
Trial: 32147225
Drug: 900 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 μg salbutamol
Trial: 33973551
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (three cycles of full-dose anthracycline and ifosfamide)
Trial: 33973551
Drug: Perioperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative systemic treatment
Trial: 35275606
Drug: Diabetes patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes patients on insulin
Trial: 35275606
Drug: Diabetes patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes patients not on insulin
Trial: 34357396
Drug: 2-hour infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion of Vasoactive Intestinal Polypeptide (VIP)
Trial: 32331036
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray + oral antidepressant (ESK+AD)
Trial: 32515747
Drug: Tablet app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet app-based dexterity training (TAD-MS) for 4 weeks, five times a week, 30 minutes per session.
Trial: 32515747
Drug: Tablet app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet app-based dexterity training (TAD-MS)
Trial: 35052995
Drug: Curasept Periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curasept Periodontal Gel (chlorhexidine-based)
Trial: 32001213
Drug: Pooled non-control
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled non-control doses group
Trial: 35738633
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m2 subcutaneously on days 1, 4, 8, and 11) and Pegylated Liposomal Doxorubicin (40 mg/m2 intravenously on day 4), every 4 weeks
Trial: 32960539
Drug: Rectal biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal biopsy
Trial: 32960539
Drug: Rectal swab
RxNorm normalized name: witch hazel .5 mL RECTAL SWAB [Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal swab
Trial: 33559433
Drug: Shao's five-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shao's five-needle therapy combined with conventional western medical treatment
Trial: 33559433
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medical treatment
Trial: 34587385
Drug: Ozanimod (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod (1 mg once daily)
Trial: 34850160
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg once-daily
Trial: 35987996
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + esketamine 0.05 mg/kg (PK1 group)
Trial: 35987996
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + esketamine 0.1 mg/kg (PK2 group)
Trial: 35987996
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + esketamine 0.2 mg/kg (PK3 group)
Trial: 32204780
Drug: Interventions aligned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions aligned with the Occupational Therapy Practice Framework: Domain and Process (3rd ed.)
Trial: 32204780
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (no specific occupational therapy intervention mentioned)
Trial: 32350785
Drug: 4 units
RxNorm normalized name: Afrezza, 4 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 units of FFP administered before separation from CPB and 4 units of FFP and 20 units of platelet concentrate administered after separation from CPB
Trial: 32350785
Drug: 8 units
RxNorm normalized name: Afrezza, 8 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 units of FFP and 20 units of platelet concentrate administered after separation from CPB
Trial: 33780264
Drug: Icotinib combined
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib combined with concurrent chemoradiotherapy (CRT)
Trial: 32778008
Drug: Low-iron formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron formula (2.3 mg/L)
Trial: 37712908
Drug: Eculizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab treatment
Trial: 34649850
Drug: Peer‐driven intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer‐driven intervention for resuming CPAP use after discontinuation.
Trial: 33830437
Drug: Metformin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (target dose 1000 mg bid)
Trial: 32268991
Drug: Herbal compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal compound (500 mg of Plantago ovata husk in 30 mL water plus three drops of vinegar per dose, used as a mouthwash)
Trial: 33239950
Drug: CHO-M (CHO-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-M (CHO-electrolyte solution + MBI)
Trial: 33239950
Drug: Control (noncarbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (noncarbohydrate solution + traveling introduction audio)
Trial: 33239950
Drug: CHO (Carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (Carbohydrate-electrolyte solution + traveling introduction audio)
Trial: 35304299
Drug: Closed incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed incision negative pressure therapy (ciNPT) dressing for 7 days
Trial: 33413353
Drug: VHA smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VHA smoking cessation medication use
Trial: 35382960
Drug: Medication disposal
RxNorm normalized name: MEDICATION DISPOSAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication disposal pouch
Trial: 35315909
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy for 3 months
Trial: 33561507
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (RT quality graded as per protocol - PP)
Trial: 33561507
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (RT quality graded as minor deviation - MiD)
Trial: 33561507
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (RT quality graded as major deviation - MaD)
Trial: 32293527
Drug: Optimised vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimised vancomycin regimen (loading dose of 25 mg/kg followed by 15 mg/kg q12h or q8h for 5 ± 1 days)
Trial: 32293527
Drug: Standard vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard vancomycin regimen (15 mg/kg q24h, q12h or q8h for 10 ± 2 days)
Trial: 34215454
Drug: GBS-NN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS-NN vaccine (100 µg adjuvanted)
Trial: 34215454
Drug: GBS-NN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS-NN vaccine (two doses of 50 µg adjuvanted)
Trial: 34215454
Drug: GBS-NN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS-NN vaccine (adjuvanted)
Trial: 34215454
Drug: GBS-NN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS-NN vaccine (two doses of 50 µg)
Trial: 34933545
Drug: Alpha-blocker agents
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker agents
Trial: 34321096
Drug: Epratuzumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab (monoclonal antibody targeting CD22)
Trial: 35504550
Drug: Topical antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antiviral therapy (TAT)
Trial: 35504550
Drug: Topical antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antiviral therapy + adjunctive antimicrobial photodynamic therapy (TAT + aPDT)
Trial: 35288009
Drug: 5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/kg carbohydrate (≤400 ml) 2 hours before surgery
Trial: 34619044
Drug: CBD (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (300 mg daily for 14 days)
Trial: 32574506
Drug: HBOT-EMI (Hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOT-EMI (Hyperbaric Oxygen Therapy and Exercise and Mental Imagery)
Trial: 34375409
Drug: Text Messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text Messaging Intervention (TMI) - 174 automated text messages plus a group smoking counseling session and provision of nicotine patches
Trial: 34569204
Drug: Acupoint application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint application of Chinese herbal medicine (Rhizome Pinelliae Preparata, Ginger, Clove) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Trial: 34569204
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received placebo plasters (flour and excipients with 10% of experimental drug concentration) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Trial: 35887701
Drug: Repetitive vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive vascular occlusion stimulus (RVOS) applied twice daily for 10 days (4 cycles of 5 min tourniquet inflation to 50 mmHg supra-systolic blood pressure, and 5 min complete deflation)
Trial: 34237973
Drug: Irrigation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation and drainage device with irrigated antibiotics
Trial: 39018512
Drug: Teriflunomide 14
RxNorm normalized name: teriflunomide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide 14 mg once daily
Trial: 35565826
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP) for 5 days
Trial: 35565826
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP)
Trial: 33846036
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin therapy
Trial: 33846036
Drug: Symptomatic care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic care and specific therapies (including intravenous aminophylline)
Trial: 35865740
Drug: 3% Kānuka
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Kānuka oil cream
Trial: 32965075
Drug: PEX168/100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEX168/100 μg
Trial: 32965075
Drug: PEX168/200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEX168/200 μg
Trial: 33606901
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop with faster-acting insulin aspart (Fiasp)
Trial: 33606901
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop with standard insulin aspart
Trial: 32894075
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose short-term memory program (placebo control)
Trial: 32824483
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg AME
Trial: 32824483
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg AME
Trial: 32211767
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Cr/d from Cr Prop
Trial: 32211767
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Cr/d from Cr Prop
Trial: 32211767
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg Cr/d from Cr Prop
Trial: 32211767
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Cr/d from Cr Prop
Trial: 32211767
Drug: 2 or
RxNorm normalized name: CP-2 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 4 mg Cr/d from Cr Prop
Trial: 35014110
Drug: High E2
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High E2 group (12 mg of E2 valerate)
Trial: 34085585
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) at 200 μg/mL
Trial: 35597370
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid supplementation to rescue therapy
Trial: 34642949
Drug: ASP0367 (bocidelpar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP0367 (bocidelpar sulfate) single doses of 1 to 120 mg
Trial: 34642949
Drug: ASP0367 (bocidelpar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP0367 (bocidelpar sulfate) multiple once-daily doses of 10 to 75 mg
Trial: 36093695
Drug: Nichi Glucan
RxNorm normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nichi Glucan 0.5g twice daily along with conventional treatment for 90 days
Trial: 36093695
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment comprising remedial behavioral therapies and L-carnosine 500 mg per day
Trial: 36381204
Drug: Intra-sacroiliac joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-sacroiliac joint methylprednisolone injection (40 mg) plus NSAIDs and sulfasalazine (2 to 3 g/day)
Trial: 36381204
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no methylprednisolone injection)
Trial: 32145825
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin 70 mg/m2 or carboplatin AUC4.5/AUC5 for GFR <50 mL/min, plus gemcitabine 1000 mg/m2 on days 1 and 8)
Trial: 33892269
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and Yoga
Trial: 34197589
Drug: Dopamine D2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2/3 receptor antagonist amisulpride (400 mg)
Trial: 34197589
Drug: Dopamine D2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2/3 receptor agonist pramipexole (0.5 mg)
Trial: 32075830
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 20 mg per day for 5 days
Trial: 33612554
Drug: 2nd-generation drug-eluting
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2nd-generation drug-eluting stents (n=59)
Trial: 34106454
Drug: platinum chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum chemotherapy and durvalumab
Trial: 34106454
Drug: chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemo-immunotherapy
Trial: 32346001
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (60% of patients)
Trial: 34822104
Drug: Venetoclax (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400-800 mg) administered with R-CHOP for eight 21-day cycles (cycle 1: days 4-10; cycles 2-8: days 1-10)
Trial: 34822104
Drug: Venetoclax (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400-800 mg)
Trial: 34822104
Drug: Venetoclax (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (800 mg) with R-CHOP
Trial: 35363510
Drug: Selumetinib (MEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (MEK inhibitor), administered twice daily for 28-day cycles until disease progression or intolerable toxicity.
Trial: 35363510
Drug: Selumetinib (MEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (MEK inhibitor)
Trial: 34247027
Drug: Melissa essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa essential oil (inhaled 2 drops for 10 min with 90-min intervals)
Trial: 34247027
Drug: Placebo (sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sunflower oil inhaled 2 drops for 10 min with 90-min intervals)
Trial: 33245118
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives for dietary self-monitoring and weekly weight loss
Trial: 32033582
Drug: Buprenorphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (10 μg/kg or 15 μg/kg)
Trial: 32033582
Drug: Naloxone (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (titrated doses)
Trial: 33944597
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (2 mL, 1 mL/nostril)
Trial: 33944597
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B (2 mL, 1 mL/nostril)
Trial: 33944597
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% NaCl) solution (2 mL)
Trial: 35086692
Drug: KVD900 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 600 mg tablet under fasted conditions
Trial: 35086692
Drug: KVD900 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 600 mg tablet
Trial: 35086692
Drug: KVD900 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 600 mg dose
Trial: 35086692
Drug: KVD900 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 (various doses)
Trial: 32107938
Drug: Lipid-lowering agents
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering agents (high-intensity statins)
Trial: 34791805
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PEG rhG‐CSF
Trial: 34791805
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 μg/kg rhG‐CSF administered when ANC reached grade 3)